Conversation

Continued Progress in the Development of Safe and Effective #RSV Immunizations

📌 Before 2023, there were no immunizing tools to protect older adults and all infants from illness due to respiratory syncytial virus (RSV).

📌 In 2023, two RSV vaccines for older adults, one of which is also approved for use in pregnant persons, and a long-acting monoclonal antibody to protect infants and some toddlers up to 19 months of age were approved by FDA and recommended by the ACIP

https://www.nejm.org/doi/pdf/10.1056/NEJMe2311862?articleTools=true